Biocept Inc, a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it has been awarded Canadian Patent 2812291, entitled Methods And Reagents For Signal Amplification. This patent covers methods for enhancing the detection of cells using fluorescent complexes, including circulating tumour cells (CTCs), and from a biological fluid. The issuance of this patent increases Biocept's total patent awards for use in its molecular diagnostics business to 40.
The method covered by this patent expands Biocept's patent protection for sensitive detection of cancer cells. It combines seamlessly with Biocept's core technologies using antibodies for CTC enrichment, as well as Biocept's microchannel intellectual property for the capture, enrichment, and imaging of CTCs from patients with cancer.
"Expanding patent protection for our Target Selector liquid biopsy platform is among our strategic priorities as we seek to grow our global business," said Michael Nall, Biocept's president and CEO. "This patent expands Biocept's international footprint for capturing and analyzing rare cells of interest, including CTCs, and is a further aid for detecting cancer cells recovered from biological fluids such as blood or cerebrospinal fluid. With this newly granted patent, we now have 40 issued patents covering our molecular diagnostic technologies, and expect to further strengthen our intellectual property position with additional patent issuances in the future."